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1. Introduction 
Opioid-related overdoses and deaths continue to increase across the United States, 
straining the substance use disorder (SUD) service sector with a growing need for recovery-
oriented services and recovery support services (Hedegaard, Warner, & Minino, 2017; Rudd, 
2016). For the purpose of this study, we define recovery-oriented services as therapeutic services 
(including both medication and behavioral therapy) that occur after SUD diagnosis, ranging from 
Level 1 (Outpatient) to Level 4 (Medically Managed Inpatient) interventions (American Society 
of Addiction Medicine, 2015). Recovery support services are non-clinical, SUD-focused services 
that address dimensions of an individual’s health, home, purpose, and community to help them 
maintain SUD treatment gains over time (Kaplan, 2008). Access to appropriate recovery-
oriented and recovery support services may be key to reducing opioid-related harms with studies 
indicating significantly reduced risks for overdoses and deaths among individuals with opioid 
use disorders (OUD) who are receiving services rather than not receiving services (Sordo et al., 
2017; Schwartz et al., 2013). For this population, access to medications for OUD is associated 
with better treatment outcomes and subsequently overall health outcomes (Volkow & Wargo, 
2018). Pharmacotherapies, including methadone, buprenorphine and naltrexone, help retain 
individuals in services and reduce risks for opioid-related harms, overdose, and death (Sordo, et 
al., 2017; Mattick, Breen, Kimber, & Davoli, 2014; Nunes et al., 2018).  
In light of these benefits, much of the extant literature has focused on understanding how 
to expand access to these medications (McElrath & Joseph, 2018; Volkow & Wargo, 2018). 
Recent policy and funding initiatives through Medicaid expansion and the Comprehensive 
Addiction and Recovery Act (2016) have supported the increased availability of medications for 
OUD through funding streams developed to address this growing epidemic (Andrilla, Moore, 
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Patterson, & Larson, 2018; Sharp et al., 2018). Yet, expanding access and use of these 
pharmacotherapies means little if individuals using them for their OUD are not concurrently able 
to access complementary recovery-oriented and recovery support services inherent to best 
practices for medication assisted treatment protocols (Kresina & Lubran, 2011; National Institute 
on Drug Abuse, 2018; Robinson & Adinoff, 2018). In fact, promoting access to on-going, 
comprehensive and holistic services is critical for this population given the highest risks for 
overdose occur both before and after treatment (Sordo et al., 2017). In other words, these 
individuals using medications for OUD would benefit from engaging in complementary 
recovery-oriented services and recovery support services to minimize their experiences of 
opioid-related harms. However, these services must exist and be willing to serve these 
individuals in order for them to benefit from receiving these services.  
Existing studies provide initial insight into how the facilities providing SUD-related 
services may be responding to service-seeking individuals who are prescribed medications for 
OUD. Several facility-level factors may contribute to whether or not a facility decides to provide 
services to individuals using these medications, including services infrastructure, stigma, service 
philosophy, and client demographics (Chang, Klimas, Wood, & Fairbairn, 2017; Hadland et al., 
2018; Livingston, Adams, Jordan, MacMillan, & Hering, 2017; Majer et al., 2018; McElrath, 
2018; Roman, Abraham, & Knudsen, 2011). For example, medical professionals on staff at 
facilities are often reluctant to prescribe and/or monitor medications for OUD due to their fears 
of working with opioid-using individuals, lack of knowledge about OUD, and/or concerns about 
surveillance duties, potentially limiting availability and support for medications for OUD at a 
given facility (Livingston et al., 2017; McElrath, 2018). It is less clear how these factors may 
affect provider preferences related to their openness to working with individuals using 
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medications for OUD within the facilities providing less intensive recovery-oriented services 
and/or recovery support services. One study observed individuals within democratically-run, 
Oxford House settings (defined as a community-based approach which is participant-run and 
provides a supportive, sober living environment) conveyed predominantly mixed-to-negative 
attitudes towards use of these medications among residents (Majer et al., 2018). The presence of 
stigma against individuals using medications for their OUD suggest abstinence-based recovery 
homes may not be optimal resources of individuals using these medications (Majer et al., 2018). 
These findings also reflect the concerns proposed by Roman and colleagues (2011) about the 
lack of alignment between use of medications for OUD and both 12-step practices and traditional 
drug- and alcohol-free settings. Client demographics may also influence facility-level acceptance 
for medication use. For example, providers often underuse medication assisted treatment 
protocols with youth likely due to provider concerns about our limited understanding of the 
utility of medications for OUD with youth (Chang et al., 2017; Hadland et al., 2018).  
This study aimed to gain further clarity on how facility-level characteristics may be 
contributing to service availability for individuals using medications for OUD and seeking 
complementary recovery-oriented services and/or recovery support services.  First, we examined 
the level of a facility’s acceptance of medications for OUD, defined by their willingness to 
provide services to individuals prescribed these medications and their level of involvement in 
managing the use of these medications. Second, we examined the facility-level characteristics 
associated with differences in facility acceptance of medications for OUD. Finally, we describe 
the reasons provided by facility representative about their rationale for a given medication 
acceptance levels. For this study, we did not capture finer grain detail about daily practices that 
may hinder treatment progress beyond service access. 
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2. Material and methods 
2.1 Census of facilities providing clinical and non-clinical services to address substance use 
We used a university-agency collaboration model to conduct a needs assessment of a 10-
county region within the Kansas City metropolitan area. It arose out of response from the Kansas 
City Opioid Treatment Work Group identifying a need for regionally specific data about service 
capacity, particularly in relation to addressing OUD-related needs, in order to minimize harms of 
increasing rates of opioid use in the region. We aimed to capture a point-in-time assessment of 
the substance use disorder (SUD) service sector between Fall 2017 and Spring 2018. We defined 
the sector broadly to include all services that provided support to individuals at risk of substance 
misuse, actively misusing alcohol and/or other drugs, or in recovery from a SUD. We collected 
multiple listings for organizations that provided at least one of the following services: 
prevention/education services; screening/assessment services; providers of medications for 
OUD; detoxification services; intervention specialists; SUD treatment services (i.e., all levels of 
care from inpatient to traditional outpatient); recovery support services (defined by provision of 
sober housing, peer supports, recovery coaching and/or management, and community supports); 
and other non-SUD support services. In addition to understanding the context of services, we 
used this information to update the referral database for a SUD-related crisis hotline and an 
associated online resource guide hosted by our community partner.  
As a first step, we obtained well-established referral listings in the metropolitan area that 
included United Way 211, My Resource Connection (Johnson County), Kansas Department of 
Aging and Disability Services (KDADS) Treatment Facility Summary, Missouri Department of 
Mental Health (DMH) Listings of Eligible Providers, and First Call Alcohol/Drug Prevention & 
Recovery Resource Guide. In addition, we pulled listings from the following online directories: 
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Substance Abuse and Mental Health Services Administration (SAMHSA) treatment locator, 
Oxford Houses, University of Kansas Medical Center (KUMC) Resource List, National 
Directory of Drug and Alcohol Abuse Treatment Listing, Addicted.org, DrugRehab.org, 
Recovery.org, FreeAddictionCenters.org, and Psychology Today. We obtained a listing of 
approved providers of medications for OUD from SAMHSA. To fill potential gaps within these 
directories, we also met with local representative of Kansas, Missouri, and Federal government 
agencies. In addition, we actively participated in three local task force/coalition meetings that 
included providers from multiple sectors serving substance-using populations. We also reached 
out to leaders within the field and leaders of agencies conducting innovative practices, who we 
identified through local media outlets, coalition meetings, and discussions with other key 
informants. Our goal was to obtain a representation of viewpoints throughout organizations 
providing services along the SUD continuum of care that ranged from screening and diagnosis to 
service linkages to recovery-oriented services to recovery support services. As a result, we spoke 
to representatives from the following groups: (1) government, private, non-profit, and faith-based 
organizations; (2) representatives from both Kansas and Missouri service sectors; and (3) 
providers offering a diverse range of services. We conducted 30 key informant interviews (10% 
government representatives, 20% non-profit executive leadership, 10% faith-based executive 
administrators, 10% social services executive administrators, 10% prescribing physicians, 10% 
prevention specialists, 10% dual diagnosis providers, and 20% recovery support services 
providers).  
As a second step, we de-duplicated the facilities identified from each of these sources to 
create a final list of 692 unique facility locations that were within the 10 county region. Finally, 
we followed procedures to obtain information from a maximum of five different source to verify 
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that each location on our list was active and providing services to clients between September 
2017 and March 2018. To track information consistently across sources, we created a long-form 
and short-form survey tool that aligned with the 2016 National Survey of Substance Abuse 
Treatment Services (NSSATS; SAMHSA, 2017). We also incorporated information from 
stakeholder interviews when relevant to understanding facility-level practices. In the end, we 
validated facility location and services through one or more of the following sources: (1) facility 
survey based on the 2016 version of the National Survey of Substance Abuse Treatment Services 
(NSSATS; SAMHSA, 2017) that was completed by facility directors; (2) web scrapes of agency 
websites with a follow-up telephone survey (using a modified short-form of the facility survey) 
with intake service specialists; (3) SAMSHA locator details updated in January 2017 using 
information from the 2016 NSSATS (SAMHSA, 2016); (5) stakeholder interviews; and/or (4) 
state summaries of eligible SUD services by location.  
We identified 216 agencies comprising 410 facility locations that served individuals with 
substance-related needs across 10 counties that captured a mix of urban and rural geographies. 
Our verification process included confirmation that that the location was currently in operation 
by at least one source. Most responses were similar across data sources; however, if there was a 
difference in information across sources, we prioritized the information that reflected the most 
up-to-date information. For example, information collected from a facility representative 
between September 2017 to March 2018 through our survey methods would be prioritized over 
data collected from an agency website or the 2016 N-SSATS. In sum, 166 (40.4%) were verified 
using 3 or more of the data sources; 230 (56.1%) were verified using 2 of the data sources; and 
14 (3.4%) were verified using 1 of the data sources. This study excluded the 50 (12.2%) facilities 
reporting that they do not treat opioid-related concerns and included the 360 (87.8%) facilities 
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reporting they provide services to clients with opioid-related concerns. Table 1 provides a 
description of the characteristics for all facilities that reported a willingness to treat clients with 
opioid-related concerns (N = 360).  
<INSERT TABLE 1 ABOUT HERE> 
2.2 Measures 
Facilities reported on their ability and/or willingness to serve individuals using 
medications for OUD on a 4 point scale that we modified from the National Survey of Substance 
Abuse Treatment Service that ranges from 1 – Medications for OUD use not allowed and/or does 
not address opioid-related concerns to 4 – Medications for OUDs administered or monitored on 
site (N-SSATS; SAMHSA, 2016). In addition, we documented when facilities reported that they 
do not accept clients with opioid-related concerns due to a prevention-only focus or not serving 
clients with opioid-used disorders to help distinguish them from facilities serving clients with 
opioid-related concerns. Excluding facilities that do not address opioid-related concerns, these 
data were recoded as follows: 1 – zero acceptance (medications for OUD use not allowed); 2 – 
low acceptance (medications for OUD use accepted with additional restrictions and/or 
reservations); 3 – moderate acceptance (medications for OUD use accepted without any 
restrictions or reservations); and 4 – high acceptance (medications for OUDs administered 
and/or monitored on site). For facilities reporting administering and/or monitoring these 
medications on site, we also collected the specific types of opioid-related medications (i.e., 
methadone, buprenorphine, or naltrexone); however, we did not track more specific information, 
such as mode of administration. Table 2 provides a summary of these distributions. Please note 
that we recoded the facility as having low acceptance if it only accepted clients on some types of 
medications for OUD (i.e., injectable vivitrol) but not other types (e.g., methadone). If a facility 
was willing to administer and monitor any type of medications for OUD, we recoded the facility 
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as high acceptance given authorizations are required for providers to prescribed specific types of 
medications. In addition, we asked facilities to provide qualitative feedback explaining their self-
reported acceptance level of medications for OUD via text in the online survey and verbally in 
the telephone-based survey (long and short form).  
<INSERT TABLE 2 ABOUT HERE> 
Given the study’s focus on assessing a broad range of facilities providing SUD-related 
services, we assessed for facility type and facility focus. Facilities reported the legal designation 
for their agency/organization for taxation purposes: for profit (1), nonprofit (2), faith based 
organization (3), or government-run (4). Each facility also reported on the primary treatment 
focus of their location: substance use disorder (SUD) treatment (1), mental health or mixed 
mental health/SUD treatment (2), general health (3), or other social services (4). 
The Midwestern region where we conducted the study has a large presence of faith-
oriented service providers within the SUD treatment field. To capture potential differences by 
spiritual orientation of actual practices, we asked facilities to rate the level of spiritual orientation 
that aligns with their daily services using the typology presented by Sider & Unruh (2004). Each 
facility reported on the spiritual characteristics of their facility by rating it as 1 - secular (agency 
has no religious identity or content); faith-partnership (agency has a partnership with a faith-
oriented organization or funder); faith-background (agency have historical ties to a faith or faith-
oriented organization but operates in more of a secular model); faith-affiliated (agency may have 
little to no religious content but does encourage religious participation); faith-centered (agency is 
explicitly religious, but participants can opt-out of religious activities); or faith-permeated 
(agency requires participation in religious elements). Based on the distribution of categories, we 
operationalized spiritual orientation as a categorical variable to distinguish between purely 
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secular (1) facilities from those with some faith orientation ranging from faith-affiliated to faith 
permeated (0).   
We documented availability of non-English language services, eligible ages for services, 
and eligible gender for services for each facility. We operationalized language services as a 
dichotomous variable for English Only (1) and English plus other language (0). We 
dichotomized age-specific services into adult only (1) and inclusion of other age groups, such as 
adolescents (0). We operationalized gender-specific services as a categorical variable using three 
categories: women only (1), men only (2), and both women and men (3).   
Facilities often provided multiple SUD services; as a result, we created non-mutually 
exclusive dichotomous variables for SUD services by level of care, guided by the American 
Society for Addiction Medicine’s level of care system (ASAM, 2015). Services included medical 
detox, acute inpatient, residential treatment, day treatment/partial hospitalization, intensive 
outpatient, traditional outpatient, and recovery support services. Based on the study criteria, 
screening/prevention/education services were excluded from this study due to the inability to 
address opioid-specific concerns.  Due to a low number of facilities reporting medical detox or 
acute inpatient services, these services were combined into one category that represented 
services provided within hospital settings, resulting in a possible range of 1 to 6 SUD services 
per facility. We also created a count for the total number of non-SUD services. Non-SUD 
services were categorized into ten possible services that reflect NIDA-recommended care that 
help to facilitate holistic and individualized treatment plans (NIDA, 2018): health/education 
services, mental health/counseling services, employment/education support, legal services, case 
management for social services referral or instrumental supports, domestic violence services, 
housing services that provided or located shelters or permanent housing, transportation services, 
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parenting supports such as child care or parenting education, and family psychoeducation and 
supports. We created a count for total number of non-SUD services per facility, with a possible 
range from 0 to 10. 
Given the chosen Metropolitan area is bisected by a state line, we controlled for the State 
(coded at State 1 and State 2) where the facility is located given substantial differences in 
policies related to funding and initiatives promoting MAT prescription and distribution.  
2.3 Analytic Procedures 
  For the quantitative data, we ran descriptive statistics and chi-square tests for 
independence. We used Stata/SE 14.0 to conduct unadjusted and adjusted multinomial logistic 
regression for our multivariate analyses; we chose this model to avoid potential bias from 
assuming parallel regression across categories as observed with ordinal logistic regression 
models (Long & Freese, 2006). We used a mlogit command in Stata 14/SE to simultaneously 
estimate binary logits for acceptance categories (i.e., zero, low, and high) compared to the base 
outcome of moderate acceptance (Long & Freese, 2006). We evaluated goodness of fit and 
conducted regression diagnostics using Stata/SE 14.0 (Long & Freese, 2006); and we ran the 
mlogitroc module to assess for model accuracy (Peterson, 2010). Coefficients from the model 
were exponentiated (ecoef) to obtain relative risk ratios (rrr). Our final analytic sample was 
composed of 350 facilities with complete information. The 10 (2.8%) cases with missing data 
were deleted case-wise. All data appeared to be missing at random with no significant 
differences observed between cases with and without missing data.  
The final multivariate model included facility focus, adult only population, recovery 
support services, multiple SUD services, multiple non-SUD services, and a control for state 
where the facility is located. To minimize multicollinearity, gender-specific service was removed 
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from the model as this variable was associated with recovery support services (primarily driven 
by housing services) and was destabilizing the model.  In addition, agency type was removed due 
to collinearity with facility focus; facility focus was maintained given it gave a more precise 
description of facility-specific activity.   We removed the variables measuring language services, 
presence of SUD services less than 20 hours/week, and presence of SUD service more than 20 
hours/week from the final model due to collinearity with the variable measuring facilities with 
multiple SUD services. We retained the variable for multi-SUD services given it better portrays 
global SUD service capacity than any one of the other individual variables.  In the unadjusted 
models, the distribution of faith-orientation resulted in inflated standard errors due to a small 
proportion of agencies reporting non-secular orientation within high acceptance facilities. Due to 
this issue in addition to 79.5% of all faith-oriented facilities reported providing recovery support 
services (χ2(1) = 34.30, p < .001), we decided to remove this variable from the final model to 
improve model fit.  
For the qualitative data, we conducted a content analysis with a final analytic sample of 
89 facilities providing rationale for their choice (Neuendorf, 2017). We used content analysis to 
help summarize a large number of brief, qualitative responses and to identify trends in rationales 
for decisions across the acceptance categories (Bengtsson, 2016; Neuendorf, 2017). After 
extracting the qualitative responses, two members of the research team coded the data using 
Excel and Nvivo 12.  We then used multiple rounds of close reading of the text to inductively 
identify categories and developed an associated codebook with definitions of what rationales fell 
into each category. Specifically, the first round of coding focused on descriptive, in vivo, and 
heuristic coding, such as “insufficient supports” (Miles, Huberman, & Saldana, 2014).  
Subsequent second round coding developed pattern codes including implicit themes revolving 
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around facility acceptance. We were unable to obtain qualitative feedback from 75.3% of 
facilities, which represents a substantial amount of missing data. Data was not missing at random 
with significant differences observed between facilities providing and not providing their 
rationale for the self-reported acceptance level of medications for OUD. Specifically, facilities 
providing rationale were observed to be composed of a higher proportion of low acceptance 
(44.9% compared to 6.1%; x2 (3) = 78.83, p < .001). It may be that representative reporting low 
acceptance felt compelled to justify the complex nature of their approach to serving clients using 
medications for OUD.  In addition, facilities providing qualitative feedback were observed to 
have a lower proportion of secular orientation (53.9% compared to 82.0%; x2(1) = 27.76, p < 
.001); a higher proportion providing recovery support services (66.3% compared to 47.9%; x2(1) 
= 9.01, p = .003); or a lower proportion providing adult only services (49.4% compared to 
68.2%; x2(1) = 10.07, p = .002). Given the low response rate to this question, we view these data 
as exploratory with limited generalizability, and we primarily used these data to contextualize the 
quantitative findings. 
3. Results 
3.1 Bivariate Analyses 
Table 1 and 2 show the univariate distributions of facility characteristics for all 360 
facilities identifying as serving clients with opioid-related needs. Among these, we observed high 
acceptance facilities reported some variation in the types of medications they were authorized to 
prescribe. Of the 90 facilities reporting ability and willingness to administer and/or monitor 
medications for OUD, 8.9% (n =8) identified as Opioid Treatment Programs administering 
methadone. Most facilities administering methadone also administered either buprenorphine (n = 
4) or naltrexone (n = 2). In addition, 53.3% (n = 48) reported prescribing buprenorphine only, 
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17.7% (n = 16) reported prescribing naltrexone only, and 20.0% (n = 18) reported prescribing 
both buprenorphine and naltrexone. 
Table 3 shows the bivariate comparisons of several facility characteristics with 
acceptance level for the 350 facilities with complete data. First, approximately 25% (n = 88) of 
the 350 facilities used in the analytic sample that were open to serving clients with opioid-related 
concerns reported zero acceptance for clients using medications for OUD. However, the 
proportion of zero acceptance facilities varied by significantly by level of care with 0% of 
facilities identifying as zero acceptance in facilities offering inpatient or medical detox services 
compared to over 40% for facilities offering recovery support services.   
<INSERT TABLE 3 ABOUT HERE> 
In addition, we observed a higher proportion of high acceptance facilities identified as 
being a part of private, for-profit organizations, likely driven by a higher proportion of these 
providers identifying as private medical providers. We observed a higher proportion of facilities 
that focused primarily on mental health and general health also identified as moderate and high 
acceptance facilities. In contrast, a higher proportion of agencies focused on SUD only or other 
services reported identifying as zero to low acceptance facilities. Acceptance level also appeared 
to significantly differ by type of services offered at a facility, including the number of SUD 
services and non-SUD services offered at a given facility location. 
3.3 Multivariate Analyses 
Table 4 shows the final adjusted model that demonstrated the best fit and alignment with 
model assumptions.  The model results in three separate regressions that compare three 
acceptance level categories (i.e., zero acceptance, low acceptance, and high acceptance) to the 
base outcome of moderate acceptance. For example, the column labeled low acceptance 
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represents the model estimating the probability that a facility reported low acceptance of 
individuals using medications for OUD (Plow) relative to the probability that a facility reported 
moderate acceptance of individuals using medications for OUD (Pmod), or the relative risk of 
(Plow)/(Pmod). We report the relative risk ratios (rrr) in Table 4, and one should interpret these as 
the ratio of relative risk for each facility characteristics similar to how we interpret odds ratios 
(Long & Freese, 2006). The final model significantly differs from the intercept-only model with 
good model fit and model accuracy with an excellent fitting ROC (AUC = 0.99).  The final 
model also met the assumption for independence of irrelevant alternatives.  
<INSERT TABLE 4 ABOUT HERE> 
We observed significant differences between zero and moderate acceptance facilities by 
facility characteristics. For facilities with a primary focus on mental health services relative to 
other types of primary focus (i.e., SUD only, general health, social services), the relative risk for 
identifying as zero acceptance (compared moderate acceptance) would be expected to decrease 
by a factor of 0.39 when all other variables in the model are held constant. In other words, 
facilities with a primary focus on mental health are less likely than facilities with another 
primary focus to identify as zero acceptance than moderate acceptance. All else being equal, the 
probability of a facility identifying as zero acceptance (compared to moderate acceptance) is 
higher for facilities providing recovery support services (compared to those not providing these 
services); however, identification as a zero acceptance facility was lower for facilities that 
provided multiple SUD services (compared to only one SUD service). We also observed the 
facilities in one state (that did not have policies promoting acceptance of individuals using 
medications for OUD) were more likely than the other state (that had recently implemented 
funding and policies promoting acceptance of individuals using medications for OUD) to 
identify as zero acceptance than moderate acceptance.  
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We observed two important distinctions between low acceptance facilities that accepted 
individuals using medications for OUD with reservations and/or additional restrictions and 
moderate acceptance facilities that accepted these individuals without reservations and/or 
additional restrictions. All else being equal, facilities offering recovery support services were 
more likely than those facilities not providing these services to identify as low acceptance than 
moderate acceptance. We also observed the relative risk for facilities identifying as a low 
acceptance facility compared to a moderate acceptance facility would be expected to decrease by 
90% for facilities providing multiple SUD services, holding all other variables constant.  
Finally, the model compared high acceptance facilities to moderate acceptance facilities. 
The relative risk of a facility administering and/or monitoring medications OUDs on site 
compared to just being unreservedly open to serving individuals using these medications 
increases by a factor of 3.22 for facilities that identifying as having a primary mental health 
focus. For facilities serving adults only relative to being open to serving children and 
adolescents, the relative risk for being a high acceptance facility (compared to moderate 
acceptance) would be expected to increase by 412% given the other variables in the model are 
held constant. Opposite to what we observed for the model comparing low acceptance to 
moderate acceptance facilities, we observed that facilities offering recovery support services 
were less likely than those facilities not providing these services to identify as high acceptance 
than moderate acceptance. In addition, facilities with multiple SUD services were more likely 
than facilities with only one SUD service to identify as high acceptance compared to moderate 
acceptance.  
3.4 Content Analysis 
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 Table 5 provides a summary of categories and subcategories that we identified from the 
89 qualitative responses that we received from facility representatives justifying their facility’s 
acceptance level.  We used this information to help us gain insight into additional factors, 
beyond facility level characteristics measured by our survey tools, which may contribute to the 
observed variation in facility acceptance of medications for OUD. 
<INSERT TABLE 5 ABOUT HERE> 
 
3.4.1 Alcohol/drug free facility. Facilities reporting use of an alcohol/drug free 
environment fell into two groups: 1) explicit statements that no narcotics were allowed and that 
they viewed medications for OUD as narcotics, and 2) more general concerns about potential 
negative impact on the therapeutic community. When looking at rationale by facility 
characteristics, we observed alcohol- and drug-free facilities where “no narcotics” were allowed 
all identified as faith-oriented facilities (χ2(1) 13.19, p < .001) and as not accepting clients using 
medications for OUD (χ2 (3) = 51.40, p < .001).  Many described that they “follow a traditional 
12-step model; no narcotics” or “do not allow any narcotics use; zero tolerance”.  In contrast, 
facilities that low acceptance of individuals using medications for OUD reported additional 
monitoring and/or stricter rules were in place to ensure the therapeutic community was not 
adversely affected by the behavior of an individual using these medications. For example, 
facilities described beliefs similar to having “reservations about how medications may impact the 
community, given their psychotropic effects. Strict rules applied to this group.”  
3.4.2 Provider preference. A high proportion of facilities reporting provider preference 
also reported a mental health focus (69.2%; χ2 (2) = 7.41, p = .025), being secular in orientation 
(92.3%; χ2 (1) = 9.02, p = .003), and not providing recovery support services (92.3%; χ2 (1) = 
23.40, p < .001). We observed this explanation to be split between facilities reporting high 
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acceptance (where providers actively chose to administer and/or monitor medications OUD) and 
facilities reporting reservations in acceptance that depended on individual provider comfort.  
3.4.3 Drug Specific Preferences. Drug-specific preferences were predominantly reported 
by facilities providing recovery services (χ2 (1) = 3.86, p = .049) and those reporting low 
acceptance of medications for OUD (χ2 (3) = 9.31, p = .025). Facilities reported more subtle 
restrictions such as drug-specific preferences, varying from preference for “Methadone or 
Vivitrol” to more specific responses that “Vivitrol okay. Methadone or suboxone are 
problematic; there is no way to monitor them, and it opens up problems." 
3.4.4 Prior Experiences. Prior experiences (whether good or bad) were associated with 
agency focus, specifically a lower proportion identifying as mental health focused (4.5%) 
compared to other focus (95.5%; χ2 (1) = 12.52, p < .001) or as a multiservice facility (9.1%) 
compared to single SUD service facility (90.9%; χ2 (1) = 9.16, p < .002). A few zero acceptance 
facilities specifically described not accepting individuals using medications for OUD “based on 
prior experience” with concerns. Low acceptance facilities that accepted individuals using 
medications for OUD with reservations and/or additional restrictions (n = 50) primarily reported 
having bad prior experiences with individuals using medications for OUD: “It depends on the 
situation. We’ve had bad experiences with methadone and suboxone. It’s also hard to tell use 
levels with a UA.” On the flipside, several moderate acceptance facilities reported having good 
experiences with individuals using medications for OUD: “Women that are on medications do 
well here.  They seem to really want to make a change for the better.”   
3.4.5 Level of Supports. Presence of sufficient supports aligns with moderate to high 
acceptance facilities. Sufficient supports were associated with agency focus on mental health (χ2 
(1) = 5.97, p = .015) with a higher proportion of facilities reporting sufficient supports also 
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identifying as having a primary mental health focus (62.5%) compared to other focus (30.1%). 
Similar patterns were observed for facilities with secular orientations (χ2 (1) = 12.45, p < .001) 
and provision of multiple SUD services (χ2 (1) = 17.38, p < .001). Specifically, moderate 
acceptance facilities reported having psychiatrists on an advisory board, physicians that actively 
partner with the agency as an outside support, or specific therapeutic programming that 
supported use of medication for OUD like the Matrix Model or harm reduction philosophies. 
Along these lines, high acceptance facilities (n = 8) described having sufficient supports for 
individuals using MATs, such as “full-time psychiatrists and medical doctors on site” were open 
to providing these services. These facilities reporting their rationale were predominantly multi-
service facilities with some type of mental health focus with psychiatrists on staff, and they do 
not reflect the physicians providing standalone services.  
In contrast, zero to low acceptance facilities specified that they has insufficient supports 
and/or training to assist individuals with needs that arise around medication management. This 
often resulted in these individuals being “referred out if medication needs present” in zero 
acceptance facilities. Many low acceptance facilities describe having “mixed reports about the 
effects of medications and having a lack of understanding regarding what medication assisted 
treatment involves” and many conveyed desire to only accept clients if their medication protocol 
and recovery was “well maintained”.  
3.4.6 No Screening/Assessment for Medications for OUD. Several facilities reported 
moderate acceptance due to the simple fact that they did not actively assess if clients were using 
of medications for OUD. These facilities all reported offering faith-oriented services (χ2 (1) = 
8.90, p = .003) and reported a primary focus on social services, typically providing recovery 
support services in lieu of recovery-oriented services.  
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4. Discussion 
4.1 Discussion of Findings 
Our study looked beyond availability of providers to prescribe medications for OUD to 
look at facility acceptance of these medications for any facility providing recovery-oriented or 
recovery support services open to clients with opioid-related needs. We identified a quarter of 
these facilities were unwilling to serve individuals using medications for OUD, particularly those 
focused on recovery support services. We also observed an additional 16% of low acceptance 
facilities (primarily less intensive recovery-oriented services like outpatient settings or recovery 
support services) who were willing to serve these individuals but may be providing less 
hospitable environments due to increased oversight and restrictions that these individuals are 
subject to due to their medication use. These observations build upon prior work that observed 
finding mixed-to-negative attitudes towards medication for OUD among residents of abstinence-
based recovery homes (Majer et al., 2018; Roman et al., 2011) by highlighting that over 40% of 
the SUD service sector in this Midwestern region were not fully open to accepting clients due to 
their medication use with mixed-to-negative attitudes. That being said, it is important to 
emphasize that factors contributing to these trends are complex and varied, providing multiple 
points for intervention at an organizational level to increase services for individuals using 
medications for OUD and in need of complementary recovery-oriented and recovery support 
services. 
Multi-service facilities and/or facilities primarily focused on mental health or mixed 
mental health-SUD are more likely to report high acceptance or moderate acceptance of 
individuals using medications for OUD. These results align with qualitative feedback that these 
agencies report having sufficient infrastructure to support individuals on these medications (such 
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as full-time psychiatrists on staff), even when receiving less intensive services.  In contrast, it 
may be that smaller facilities focused on one type of SUD service that are less intensive than 
medical detox/inpatient settings are the most difficult to access for individuals using medications 
for OUD due to zero to low acceptance. This is particularly true for facilities offering recovery 
support services, such as sober living and peer navigation services, within this study’s region. 
This finding is concerning given lower levels of care and recovery support services are critical 
during an individual’s post-treatment stabilization in the community, and they can serve to 
reinforce medication compliance necessary for relapse prevention over time (Ma et al., 2018; 
Nunes et al., 2018).  
Smaller, stand-alone facilities with fewer resources reported a lower likelihood of 
providing services to individual using medications due to concerns that they lacked the necessary 
tools to serve these individuals adequately. In addition, underlying stigma towards medications 
for OUD discussed in prior works persisted within our study’s service sector (McElrath, 2018), 
particularly in facilities providing recovery support services, where representatives reported bad 
experiences of individuals using medications over the past 10 to 20 years. Facility settings based 
on traditional 12-step or moralistic models of SUD reinforced the stigma, with medications 
viewed as continued use of psychoactive substances. In fact, our qualitative feedback aligns with 
prior work that suggests provider preference not to treat individuals using medications for OUD 
also limits availability of services for these individuals (Livingston et al., 2017); to address the 
limited number of providers available to prescribe, monitor, and provide behavioral therapy goes 
beyond basic training needs and will require addressing provider perceptions and fears. The 
development of injectable naltrexone may have shifted some concerns regarding daily 
management of medication use. However, the preference for injectable naltrexone is somewhat 
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concerning given the limited evidence base for this medication being more effective than 
methadone or buprenorphine (Lee et al., 2018; Tanum et al., 2017) and contradicts best practices 
to match treatment protocols to the individual needs of the client (NIDA, 2018).  
4.2 Strengths & Limitations 
These findings should be interpreted with key strengths and limitations in mind. This 
study is limited to an assessment of one Midwestern metropolitan area, providing insight into 
service trends that may not be duplicated in other metropolitan areas in the United States but can 
serve as a starting point for exploration of critical gaps in serving the needs of individuals using 
medications for their opioid use disorder. In addition, this study identified and contacted a census 
of facilities in the metropolitan area providing services to populations at-risk for, in need of 
treatment for, or in recovery from SUDs. It is likely we did not capture facilities that were not 
listed in existing referral databases, did not participate in local coalitions, or were not licensed 
through state organizations. Specifically, the use of one question regarding acceptance of 
medications for OUD limits our understanding of how facilities representatives interpreted this 
question. To address this limitation, we asked a follow-up question to provide an opportunity for 
facilities to provide a justification for their acceptance level. However, missingness observed in 
the qualitative responses limits our generalization of these qualitative findings. Instead, we view 
the facilities’ qualitative justifications as helping to provide some clarification regarding the 
complex range of concerns that may be driving these differences across facilities. The study also 
offset potential bias in facilities positively self-reporting their facility services by triangulating 
multiple sources of information, including engaging both facility-level directors in a formal 
survey and intake workers through a short-form survey. Finally, we did not survey or interview 
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the consumers of these services. This data best represents the experiences and perspectives of 
policy-makers, funders, coalition members, and/or providers.  
4.3 Implications for Policy, Practice, & Research 
To ensure minimizations of opioid-related harms, states must move beyond funding 
increased access to medications for OUD by also leveraging funding to build infrastructure to 
support the treatment and recovery needs of individuals with opioid use disorder across 
recovery-oriented care and recovery support services. For example, motivating psychiatrists and 
recovery services to collaborate through funding mechanisms that establish create partnerships 
across providers may initially address infrastructure concerns for smaller, stand-alone providers. 
Our findings suggest these partnerships may be particularly critical for recovery support services. 
These types of strategies can help to promote medication adherence that is associated with 
lowered relapse and mortality rates (Ma et al., 2018; Nunes et al., 20108). In addition, trainings 
need to target providers beyond the medical/mental health fields to address hesitations/concerns 
about medications of OUD. This form of outreach may be more effective through providing 
education about the benefits and harms associated with each medication, explicitly facilitating 
discussions about navigating the challenges that providers face when serving individuals using 
medications and exploring the tensions between abstinence only and harm reduction treatment 
models (Sederer & Marino, 2018).  
Future research would benefit from further exploring the factors identified with zero and 
low acceptance facilities that have emerged. For example, more information is needed to 
understand the history of self-reported “bad experiences” with medications for OUD. More in-
depth exploration may help policy makers, administrators, and providers better understand the 
sources of reservations or fears. In addition, further examination of this information can provide 
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insight into the specific infrastructural and training needs among zero and low acceptance 
facilities.  
4.4 Conclusions  
To support the individuals who are increasingly being prescribed medications for OUDs, 
providers of recovery-oriented and recovery support services need to be actively engaged to 
identify potential hesitations or concerns about treating this population and to be educated about 
the medications available. Specifically, there is a need to develop funding for education, training, 
and infrastructure that actively address the gap in available services open to individuals using 
medications for OUD, particularly for facilities offering recovery support services. These 
services are critical to support individuals in their long-term recovery and reduce post-treatment 
relapse, overdose, and deaths. Without these changes, our efforts to expand access and use of 
medications for OUD may fall short as individuals being prescribed these medications have even 
fewer options of where they can obtain complementary therapeutic services and/or recovery 
support services.  
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RUNNING HEAD: MOUD Acceptance 
Table 1: Characteristics of Facilities Willing to Serve Clients with Opioid-related Needs (N = 360) 
Facility Characteristics Count (%) 
Facility type (legally defined for taxation purposes)  
   Private, for profit 134 (37.2) 
   Private, nonprofit 198 (55.0) 
   Other 28 (7.8) 
Facility focus   
   SUD prevention/treatment only 170 (47.2) 
   MH treatment or mixed MH/SUD treatment 142 (39.4) 
   General health 9 (2.5) 
   Other 39 (10.8) 
Level of spiritual orientation (practice-defined)  
   Secular 266 (74.3) 
   Faith partnership, background, or affiliation 10 (2.8) 
   Faith background 5 (1.4) 
   Faith affiliation 19 (5.3) 
   Faith-centered 37 (10.3) 
   Faith-permeated 21 (5.9) 
   Missing 2 (0.0) 
Language services  
   English only 107 (29.7) 
   English plus other language services 253 (70.3) 
Age-specific services  
   Adult only (ages 18+ years) 133 (36.9) 
   Other ages (adolescent also served) 227 (63.1) 
Gender-specific services  
   Women only 42 (11.7) 
   Men only 67 (18.7) 
   Both women & men 250 (69.6) 
   Missing 1 (0.0) 
Accept Medicaid/Medicare reimbursement?  
   No 158 (43.9) 
   Yes 116 (32.2) 
   Missing 86 (23.9) 
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Table 2: Services Provided by Facilities Willing to Serve Clients with Opioid-related Needs (N = 360) 
Facility Characteristics 
Count (%) / 
Mean (SD) Min Max 
SUD Services by level of care (non-mutually exclusive):    
   Recovery Support Services 189 (52.5)   
         Recovery management/coaching 89 (24.7)   
         Peer navigators 88 (24.4)   
         Recovery housing 126 (35.0)   
         Recovery community centers/spaces 2 (56.0)   
   Traditional outpatient 170 (47.5)   
   Intensive outpatient 87 (24.3)   
   Day treatment/partial hospitalization 15 (4.2)   
   Residential 29 (8.1)   
   Hospital-based inpatient/medical detox 14 (3.9)   
   Missing 2 (0.0)   
Number of SUD services offered 1.62 (0.05) 1 6 
    
Non-SUD services offered (non-mutually exclusive):    
   Health  78 (21.7)   
   Mental health 146 (40.7)   
   Employment/education 72 (20.1)   
   Legal 10 (2.8)   
   Case management 125 (34.8)   
   Interpersonal violence 34 (9.5)   
   General housing/shelter services 150 (41.8)   
   Transportation 38 (10.6)   
   Parenting 32 (8.9)   
   Family Support 65 (18.1)   
   Missing 1 (0.0)   
Number of non-SUD support services offered 2.09 (0.09) 0 8 
    
Acceptance of Medications for Opioid Use Disorder (OUD)     
   Zero Acceptance 88 (24.4)   
   Low Acceptance 56 (15.6)   
   Moderate Acceptance 116 (32.2)   
   High Acceptance 90 (25.0)   
   Missing 10 (2.8)   
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Table 3: Acceptance of Medications for OUD by Facility Characteristics (N = 350) 
 Facility Acceptance Level of Medications for OUD  
Facility Characteristics 
Zero 
Acceptance 
N = 88 
n (%) 
Low 
Acceptance 
N = 56 
n (%) 
Moderate 
Acceptance 
N = 116 
n (%) 
High 
Acceptance 
N = 90 
n (%) 
χ2 
(p value) 
Agency Type     33.70  
   Private, for-profit  15 (11.7) 16 (12.5) 45 (25.2) 52 (40.6) (< .001) 
   Other 73 (32.9) 40 (18.0) 71 (32.0) 28 (17.1)  
Facility focus     99.17  
   SUD only 67 (39.9) 26 (15.5) 52 (31.0) 23 (13.7) (< .001) 
   MH/Mixed MH-SUD 9 (6.6) 15 (10.9) 51 (37.2) 62 (45.3)  
   General health 0 (0.0) 0 (0.0) 4 (44.4) 5 (55.6)  
   Other 12 (33.3) 15 (41.7) 9 (25.0) 0 (0.0)  
Spiritual orientation     39.87  
   Secular 64 (24.4) 29 (11.1) 82 (31.3) 87 (33.2) (< .001) 
   Faith Orientation 24 (27.3) 27 (30.7) 34 (38.6) 3 (3.4)  
Language services     33.32  
   English only 80 (32.9) 40 (16.5) 62 (25.5) 61 (25.1) (< .001) 
   Multiple languages 8 (7.5) 16 (15.0) 54 (50.5) 29 (27.1)  
Age-specific services     22.68  
   Adult Only 69 (31.1) 29 (13.1) 59 (26.6) 65 (29.3) (< .001) 
   Other Ages 19 (14.8) 27 (21.1) 57 (44.5) 25 (19.5)  
Gender-specific services     136.15  
   Women only 22 (52.4) 9 (21.4) 9 (21.4) 2 (4.8) (< .001) 
   Men only 45 (67.2) 13 (19.4) 9 (13.4) 0 (0.0)  
   Both women & men 21 (8.7) 34 (14.1) 98 (40.7) 88 (36.5)  
Inpatient/Medical Detox     17.94  
   Not Present 88 (26.2) 56 (16.7) 112 (33.3) 80 (23.8) (< .001) 
   Present 0 (0.0) 0 (0.0) 4 (28.6) 10 (71.4)  
Day Tx/Residential     8.66  
   Not Present 81 (26.3) 54 (17.5) 96 (31.2) 77 (25.0) (.034) 
   Present 7 (16.7) 2 (4.8) 20 (47.6) 13 (31.0)  
Outpatient/IOP Services     54.35  
   Not Present 70 (39.1) 30 (16.8) 32 (17.9) 47 (26.3) (< .001) 
   Present 18 (10.5) 26 (15.2) 84 (49.1) 43 (25.1)  
Recovery support services     106.05 
   Not Present 11 (6.6) 19 (11.4) 57 (34.3) 79 (47.6) (< .001) 
   Present 77 (41.8) 37 (20.1) 59 (32.1) 11 (6.0)  
Number SUD services     48.71  
   1 service only 72 (33.3) 48 (22.2) 53 (24.5) 43 (19.9) (< .001) 
   2+ services 16 (11.9) 8 (6.0) 63 (47.0) 47 (35.1)  
Number non-SUD services     26.15  
   0 to 1 services 69 (28.7) 27 (11.3) 70 (29.2) 74 (30.8) (< .001) 
   2+ services 19 (17.3) 29 (26.4) 46 (41.8) 16 (14.5)  
Note: All cases with missing information were excluded from all analysis (n = 10). 
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Table 4: Adjusted relative risk ratios (RRRs) and 95% confidence intervals (CIs) from multinomial logistic 
regressing the probability of facility acceptance level on facility characteristics (N = 350) 
 Relative Risk Ratios (RRRs) and 95% Confidence Intervals 
Facility Characteristics Zero Acceptance 
N = 88 
Low Acceptance 
N = 56 
High Acceptance 
N = 90 
Primary mental health    0.39 [0.16, 0.96]*    0.75 [0.32, 1.76]    3.22 [1.57, 6.62]** 
Adult only services    0.90 [0.41, 1.99]    0.50 [0.23, 1.12]    5.12 [2.44, 10.77]*** 
Recovery support services    7.91 [3.24, 19.28]***    2.84 [1.18, 6.86]*   0.13 [0.06, 0.29]*** 
Multiple SUD services     0.17 [0.08, 0.38]***    0.10 [0.04, 0.24]***   2.86 [1.36, 6.01]** 
Multiple non-SUD services     0.49 [0.23, 1.03]     1.39 [0.67, 2.90]   0.49 [0.23, 1.05] 
State 1    2.61 [1.31, 5.19]**    0.77 [0.36, 1.64]   0.86 [0.44, 1.67] 
Intercept    0.51 [0.17, 1.59]       0.83 [0.31, 2.21]   0.19 [0.07, 0.55]** 
Fit Statistics    
Intercept-only log-likelihood -474.452   
Final model log-likelihood -342.487   
Likelihood Ratio χ2 (df = 21) 263.929***   
*  p < .05, **p < .01, ***p < .001  
Note: All outcome category groups are compared to the base outcome category of moderate acceptance (n = 116), 
defined by willingness to admit a client using medications for OUD without any addition restrictions and/or 
reservations. 
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Table 5: Rationale Provided by Facility Representative to Justify Acceptance Level (N = 89) 
 
 Facility Acceptance Level of Medications for Opioid Use Disorder 
Category/Sub-Category 
Zero  
Acceptance 
N = 16 
Low  
Acceptance 
N = 50 
Moderate 
Acceptance 
N = 25 
High 
Acceptance 
N = 8 
Alcohol/drug free facility 10 5 0 0 
   No narcotics allowed 10 0 0 0 
   Concern re: community impact 0 5 0 0 
Provider preference 0 5 0 4 
Drug-specific preferences 0 7 0 0 
   Injectable Vivitrol only 0 5 0 0 
   Injectiabel Vivitrol or  
        Methadone okay 
0 1 0 0 
   Short-term medication use only 0 1 0 0 
Prior experiences 2 21 5 0 
   Bad experience 2 21 0 0 
   Good experience 0 0 5 0 
Level of supports 4 12 18 4 
   Insufficient supports/training 4 11 0 0 
   Sufficient supports/training 0 0 12 4 
   Outside support required 0 1 6 0 
Does not assess for medications 0 0 4 0 
 
 
